Semax and Selank: Research Origins from the Same Russian Institute

Two peptides come out of the same Moscow research institute, get grouped together in nearly every nootropic stack guide online, and do almost nothing alike once you look at what they’re actually built to do. That’s not a contradiction. It’s the point. Semax and Selank were designed to solve two different problems, and understanding why makes both of them easier to reason about on their own terms.

Semax: built from a stress hormone, stripped of its stress hormone activity

Semax was developed in 1982 by Nikolay Myasoedov and Igor Ashmarin at the Institute of Molecular Genetics of the Russian Academy of Sciences. It’s built from a fragment of ACTH, adrenocorticotropic hormone, specifically the 4-7 segment that carries neurotrophic activity without the hormonal effects on the adrenal glands that come with full ACTH. A synthetic Pro-Gly-Pro extension was added to slow the fragment’s natural degradation, since the unmodified sequence broke down too quickly to be useful.

What’s left is a compound studied almost entirely for what it does to brain tissue rather than the endocrine system. Its most consistently documented effect is upregulating brain-derived neurotrophic factor, BDNF, which supports neuron survival, synaptic growth, and the kind of plasticity that underlies learning and memory. Intranasal administration has been shown to raise BDNF mRNA in the rat hippocampus and frontal cortex within 30 to 90 minutes of dosing (Medvedev et al.). Semax also engages the melanocortin system, the same receptor family ACTH itself belongs to, and in cerebral ischemia models it has been associated with reduced infarct volume and suppressed neuroinflammatory markers.

Semax carries real regulatory weight in Russia specifically. It’s formally approved there in two formulations, a lower concentration for cognitive support and a higher one for acute neurological conditions including stroke, and it was added to Russia’s List of Vital and Essential Drugs in 2011.

Selank: built from an immune fragment, repurposed for anxiety

Selank has a completely different origin. It’s a synthetic analog of tuftsin, a naturally occurring tetrapeptide produced when immunoglobulin G is cleaved, and it was developed at the same Institute of Molecular Genetics working alongside the Zakusov Institute of Pharmacology. Like Semax, a Pro-Gly-Pro extension was added, this time to convert tuftsin’s largely immune-focused activity into something that could cross into the central nervous system and act as an anxiolytic.

Selank’s mechanism runs through a different system entirely. Rather than binding directly to a receptor the way a benzodiazepine does, research shows Selank modulates the expression of genes involved in GABAergic neurotransmission, including subunits of the GABA-A receptor itself, GABA transporters, and the enzymes that synthesize GABA (Volkova et al.). That’s a transcriptional effect, not a direct allosteric one, which is part of why the research literature frames it as adjusting signaling balance rather than sedating the system outright. A separate 2008 study found Selank also upregulates BDNF expression in the rat hippocampus, giving it a neuroplasticity angle that overlaps, in a small way, with what Semax does through an entirely different starting point (Inozemtseva et al.).

Extensive literature, limited independent replication

Here’s where both compounds share the same honest limitation, even though their mechanisms don’t overlap. The research base for each one is genuinely large, decades of work, much of it methodologically serious, and both hold formal regulatory approval in Russia. But that body of evidence is concentrated almost entirely in Russian-language journals and Russian research institutions. Large, independent trials run by researchers outside that system are still limited, and neither compound is approved by the FDA, the EMA, or any Western regulator. That doesn’t make the existing research wrong. It means the question of how well those findings generalize outside the population and labs where they were produced hasn’t been fully answered yet.

Semax and Selank aren’t competing for the same job, and they’re not interchangeable substitutes for one another. One is built around cognitive activation through a stress hormone fragment. The other is built around calming a signaling system through an immune fragment. Different starting materials, different receptor systems, different questions being asked, from the same institute in Moscow.

References

Inozemtseva, L. S., et al. “Selank Increases the Expression of Brain-Derived Neurotrophic Factor in Rat Hippocampus.” Doklady Biological Sciences, 2008.

Medvedev, V. I., et al. “Semax, an Analogue of Adrenocorticotropin(4-10), Neurophysiological Properties.” Neuroscience and Behavioral Physiology, 2006.

Volkova, Anastasiya, et al. “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology, vol. 7, 2016, article 31.